GSK and Pfizer have settled a lawsuit alleging Pfizer’s RSV shot Abrysvo infringed GSK’s patents. A Pfizer ...
GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...
As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...
Pfizer (PFE) and GSK (GSK) settle RSV vaccine patent lawsuit, dismissing the case with prejudice. REad more here.
GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...
1d
Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...
British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...
It reported revenues of 38.41 million yuan in the first half of 2024 and a net loss of 903 million yuan, hit by falling ...
Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...
The latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of ...
Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) ...
Learn more about whether Corcept Therapeutics Incorporated or GSK plc is a better investment based on AAII's A+ Investor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback